Skip to main content
SpringerLink
Log in

Polypharmazie in der Behandlung von Persönlichkeits-und Verhaltensstörungen

  • Chapter
Polypharmazie in der Behandlung psychischer Erkrankungen

  • 1097 Accesses

Zusammenfassung

Die modernen Klassifikationssysteme DSM-IV (APA, 1994) und ICD-10 (WHO, 1994) sprechen von einer Persönlichkeitsstörung, wenn zeitlich überdauernde und unflexible Verhaltens-, Gefühls- und Denkmuster vorhanden sind, die merklich von den Erwartungen der soziokulturellen Umgebung abweichen und sich in einem breiten Spektrum sozialer und persönlicher Situationen bemerkbar machen. Diese Persönlichkeitszüge sollen in klinisch bedeutsamer Weise zu Leiden oder Beeinträchtigung in sozialen, beruflichen oder anderen wichtigen Funktionsbereichen führen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. APA (1994) Diagnostisches und Statistisches Manual Psychischer Störungen DSMIV, dt. Bearbeitung und Einleitung: Saß H, Wittchen HU, Zaudig M (1996). Hogrefe Verlag, Göttingen Bern Toronto Seattle

    Google Scholar 

  2. APA (2001) Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 158 [Suppl]: 1–52

    Google Scholar 

  3. Bellino S, Paradiso E, Bogetto F (2006) Efficacy and tolerability of quetiapine in the treatment of borderline, personality disorder: A pilot study. J Clin Psychiatry 67: 1042–1046

    Article  CAS  PubMed  Google Scholar 

  4. Benedetti F, Barbini B, Campori E, Colombo C, Smeraldi E (1998) Patterns of mood variation during antidepressant treatment. J Affect Disord 46: 133–139

    Article  Google Scholar 

  5. Berger P, Sachs G, Amering M, Holzinger A, Bankier B, Katschnig H (2004) Personality disorder and social anxiety predict delayed response in drug and behavioural treatment of panic disorder. J. Affect Disord 80 (1): 75–78

    Article  PubMed  Google Scholar 

  6. Bogenschutz MP, George NH (2004) Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65: 104–109

    CAS  PubMed  Google Scholar 

  7. Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological, model of temperament and character. Arch Gen Psychiatry 50: 975–990

    CAS  PubMed  Google Scholar 

  8. Coccaro EF (1997) Assessment of life history of aggression: development and psychometric characteristics. Psychiatry Res 73: 147–157

    Article  CAS  PubMed  Google Scholar 

  9. Cowdry RW, Gardner DL (1988) Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and trancylpromine. Arch Gen Psychiatry 45 (2): 111–119

    CAS  PubMed  Google Scholar 

  10. Dammann G, Walter M (2003) Zur Differenzialdiagnose psychotischer Symptome bei Jugendlichen und jungen Erwachsenen mit Borderline Störungen. Psychiatrische Praxis 30: 304–311

    Article  PubMed  Google Scholar 

  11. Davis M (1997) Neurobiology of fear response: the role of the amygdala. J Neuropsy chiatry Clin Neurosci 9 (3): 382–402

    CAS  Google Scholar 

  12. De la Fuente JM, Lotstra F (1994) A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol (4): 479–486

    Article  PubMed  Google Scholar 

  13. Donegan NH, Sanislow CA, Blumberg HP, Fulbright RK, Lacadie C, Skudlarski P, Gore JC, Olson IR, McGlashan TH, Wexler BE (2003) Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry 54 (11): 1284–1293

    Article  PubMed  Google Scholar 

  14. Frankenburg FR, Zanarini MC (2002) Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 63: 442–446

    CAS  PubMed  Google Scholar 

  15. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361 (9358): 653–661

    Article  CAS  PubMed  Google Scholar 

  16. Gloagen V (1998) A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 49: 59–72

    Article  Google Scholar 

  17. Hamer DH, Greenberg BD, Sabol SZ, Murphy DL (1999) Role of the serotonin transporter gene in temperament and character. J Personality Disord 13 (4): 312–328

    CAS  Google Scholar 

  18. Herpertz SC, Dietrich TM, Wenning B, Erberich SG, Krings T, Thron A, Sass H (2001) Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry 50: 292–298

    Article  CAS  PubMed  Google Scholar 

  19. Herpertz SC, Saß H (2002) Persönlichkeitsstörungen. In: Ahrens S, Schneider W (Hrsg) Lehrbuch für Psychosomatische Medizin. Schattauer, Stuttgart, S 115–124

    Google Scholar 

  20. Herpertz SC, Saß H (2003) Persönlichkeitsstörungen Thieme, Stuttgart New York

    Google Scholar 

  21. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller HJ; WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) (2007) Guidelines for biological treatment of personality disorders. World J Biol Psychiatry 8(4): 212–44

    Article  PubMed  Google Scholar 

  22. Herpertz SC (2008) Persönlichkeitsstörungen. In: Holsboer D, Gründer G, Benkert O (Hrsg) Handbuch der Psychopharmakotherapie. Springer, Berlin Heidelberg New York Tokyo, S 1007–1022

    Chapter  Google Scholar 

  23. Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ (2001) A preliminary double-blind placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin, Psychiatry 62: 199–203

    CAS  Google Scholar 

  24. Kapfhammer HJ (2003) Pharmakotherapie bei Persönlichkeitsstörungen. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme, Stuttgart New York, S 152–164

    Google Scholar 

  25. Kavoussi RJ et al (1994) An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 55 (4): 137–141

    CAS  PubMed  Google Scholar 

  26. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J (2000) A comparison of nefazodone, the cognitive-behavioral-analysis system of psycho-therapy, and their combination fort he treatment of chronic depression. N Engl J Med 342: 1462–1470

    Article  CAS  PubMed  Google Scholar 

  27. Keshavan M, Shad M, Soloff P, Schooler N (2004) Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 71 (1): 97–101

    Article  PubMed  Google Scholar 

  28. Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ (2003) Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 64 (6): 628–634

    CAS  PubMed  Google Scholar 

  29. Kopp B, Wolff M, Hruska C, Reischies F (2002) Brain mechanisms of visual encoding and working memory in psychometrically identified shcizotypal individuals and after acute administration of haloperidol Psychophysiology 39: 459–470

    Article  PubMed  Google Scholar 

  30. Leyton M, Okazawa H, Diksic M, Pars J, Rosa P, Mzengeza S, Youn SN Blier P, Benkelfat C (2001) Brain Regional alpha-[11c]methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry 158: 775–782

    Article  CAS  PubMed  Google Scholar 

  31. Liebowitz MR, Heimberg RG, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF (1999) Cognitive behavioral group-therapy versus phenelzine in social phobia: long-term outcome. Depression & Anxiety 10: 89–98

    Article  CAS  Google Scholar 

  32. Liebowitz MR, Gelenberg AJ, Munjack D (2005) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62: 190–198

    Article  CAS  PubMed  Google Scholar 

  33. Markovitz PJ (1991) Fluoxetine in the treatment of borderline, and schizotypal personality disorders. Am J Psychiatry 148 (8): 1064–1067

    CAS  PubMed  Google Scholar 

  34. Mobascher A, Mobascher J, Schmahl C, Malevani J (2007) Behandlung der Borderline Persönlichkeitsstörung mit atypischen Antipsychotika. Nervenarzt 78: 1003–1013

    Article  CAS  PubMed  Google Scholar 

  35. Norra C, Mrazek M, Tuchtenhagen F, Gobbele R, Buchner H, Sass H, Herpertz SC (2003) Enhanced intensity dependenceas a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiatric Res 37: 23–33

    Article  Google Scholar 

  36. Nosè M, Cipriani A, Biancosino B, Grassi L, Barbui C (2006) Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 21: 345–353

    Article  PubMed  Google Scholar 

  37. Pinto OC, Akiskal HS (1998) Lamotrigine as a promising approach to borderline personality disorder: an open case series without concurrent DSM-IV major mood disorder. J Affect Dis 51: 333–343

    Article  CAS  PubMed  Google Scholar 

  38. Reynolds CF et al (1999) Nortriptyline and interpersonal psychotherapy as maintainance therapies for recurrent major depression: a randomized controlled trial inpatients older than 59 years. JAMA 281: 39–45

    Article  CAS  PubMed  Google Scholar 

  39. Rickels K, Mangano R, Khan A (2004) A double-blind, placebo-controlled trial of a flexible dose of venlafaxine in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacology 24: 488–496

    Article  CAS  Google Scholar 

  40. Rinne T, van den Brink W, Wouters L, van Dyck R (2002) SSRI-Treatment of Borderline-Personality Disorder. A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159 (12): 2048–2054

    Article  PubMed  Google Scholar 

  41. Robbins TW, Everitt BJ (1996) Neurobehavioural mechanism of reward and motivation. Curr Opin Neurobiol 6 (2): 228–236

    Article  CAS  PubMed  Google Scholar 

  42. Rocca P, Marchiaro L, Cocuzza E, Bogetto F (2002) Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 62: 241–244

    Google Scholar 

  43. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E (1995) Effect of fluoxetine on anger in symptomatic volounteers with borderline personality disorder. J Clin Psychopharmacol 15: 23–29

    Article  CAS  PubMed  Google Scholar 

  44. Schneier FR, Gortz D, Campeas R, Fallon B, Marshall R, Liebovitz MR (1998) Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172: 70–77

    Article  CAS  PubMed  Google Scholar 

  45. Shea MT, Stout R, Gunderson J, Morey LC, Grilo CM, McGlashan T, Skodol AE, Dolan-Sewell R, Dyck I, Zanarini MC, Keller MB (2002) Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry 159 (12): 2036–2041

    Article  PubMed  Google Scholar 

  46. Siever LJ, Davis KL (1991) A psychobiological, perspective on the personality disorders. Am J Psychiatry 148: 1647–1658

    CAS  PubMed  Google Scholar 

  47. Soler J, Pasqul JC, Campins JJ (2005) Double-blind, placebo-controlled study of dialectical behaviour therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162: 1221–1224

    Article  PubMed  Google Scholar 

  48. Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM (2000) A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 47: 540–547

    Article  CAS  PubMed  Google Scholar 

  49. Soloff PH, Kelly, TM, Strotmeyer SI et al (2003) Impulsivity, gender, and response to fenfluramine challenge in borderline personality disorder. Psychiatry Res 119: 11–24

    Article  CAS  PubMed  Google Scholar 

  50. Stein DJ, Versiani M, Hair T, Kumar R (2002) Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 59: 1111–1118

    Article  CAS  PubMed  Google Scholar 

  51. Steinberg BJ (1995) The, cholinergic and noradrenergic neurotransmitter systems affective instability in borderline personality disorder. In: Biological and neurobehavioral studies in borderline personality disorder. American Psychiatry Press, Washington DC, pp 41–59

    Google Scholar 

  52. Torgersen S, Kringlen E, Cramer V (2001) The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 58: 590–596

    Article  CAS  PubMed  Google Scholar 

  53. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebovitz MR, Amre R (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161: 353–360

    Article  CAS  PubMed  Google Scholar 

  54. Wälte D (2003) Selbstunsichere Persönlichkeitsstörung. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme, Stuttgart New York, S 117–131

    Google Scholar 

  55. WHO Weltgesundheitsorganisation (1994) Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F) Forschungskriterien. Hans Huber, Bern Göttingen Toronto Seattle

    Google Scholar 

  56. Zanarini MC, Frankenburg FR (2001) Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62: 849–854

    CAS  PubMed  Google Scholar 

  57. Zanarini MC, Frankenburg FR (2003) Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind placebo-controlled pilot study. Am J Psychiatry 160: 167–169

    Article  PubMed  Google Scholar 

  58. Zanarini MC, Frankenburg FR, Vujanovic AA, Hennen J, Reich DB, Silk KR (2004) Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission. Acta Psychiatr, Scand 110 (6): 416–420

    Article  CAS  Google Scholar 

  59. Zanarini MC, Frankenburg FR, Parachini EA (2004) A preliminary, randomized trial of fluoxetine, olanzapine and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65: 903–907

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universität Rostock, Gehlsheimerstraße 20, 18147, Rostock, Deutschland

    Dr. med. Viola Habermeyer & PD Dr. med. Elmar Habermeyer

Authors
  1. Dr. med. Viola Habermeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. med. Elmar Habermeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag/Wien

About this chapter

Cite this chapter

Habermeyer, V., Habermeyer, E. (2009). Polypharmazie in der Behandlung von Persönlichkeits-und Verhaltensstörungen. In: Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/978-3-211-79826-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-79826-3_5

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-79825-6

  • Online ISBN: 978-3-211-79826-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation